Roche Secures Global Rights to Simcere’s Trispecific B-Cell Antibody in $1.53B Deal

Key points

• Roche will pay $75 million upfront for exclusive global rights to develop and commercialize SIM0660.
• The total deal value reaches $1.53 billion, including milestones and double-digit royalties on net sales.
• SIM0660 targets CD79a, CD19, and CD3 to trigger T-cell mediated killing while limiting cytokine release.
• The asset is designed for B-cell-mediated diseases, including cases resistant to prior CD20 or CD19 therapies.
• This is Roche’s second large licensing deal in a week, following a $2.5 billion agreement with Hanmi Pharmaceutical.

Background

This transaction follows Roche’s recent acquisition of a UCN2 analog from Hanmi Pharmaceutical in August 2026, which was valued at up to $2.5 billion. Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, has previously out-licensed assets to AbbVie, NextCure, and Boehringer Ingelheim, totaling over $6.1 billion in potential aggregate value. The parent company, Simcere, has a history of partnering with global pharma firms, including a deal with G1 Therapeutics for the bone marrow protection therapy Cosela.

How outlets are covering it

Fierce Biotech highlights the strategic fit of SIM0660 for patients previously treated with CD20 or CD19 therapies, emphasizing the dual-targeting mechanism. The Manila Times confirms the exclusive nature of the license but provides limited detail on the financial structure. Marketscreener notes the deal within the context of Roche’s broader pipeline execution and recent FDA approvals, such as the priority review for Enspryng, but does not detail the specific mechanism of action. All sources agree on the $1.53 billion total value and the $75 million upfront payment, but only Fierce Biotech details the specific antigens (CD79a, CD19, CD3) targeted by the trispecific antibody.

Why it matters

The acquisition strengthens Roche’s position in the B-cell-mediated disease space, a sector with growing demand for therapies that overcome resistance to standard treatments. The deal also underscores Simcere’s strategy of monetizing its pipeline through out-licensing, having secured over $6.1 billion in aggregate deal value. For Roche, this move diversifies its pipeline beyond its recent focus on cardiometabolic and autoimmune conditions, addressing a critical need in oncology and immunology.

What to watch

Roche will lead the development and commercialization of SIM0660 globally. Simcere Zaiming will receive milestone payments as development targets are met and royalties on future sales. The next step involves advancing the preclinical asset into clinical trials to validate its efficacy in B-cell-mediated diseases, particularly in patients who have failed prior therapies.